Taghavi K, Sharpe C, Stringer M D
Department of Paediatric Surgery, Wellington Children's Hospital, Wellington, New Zealand; Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand.
School of Medicine, University of Otago, Wellington, New Zealand.
J Pediatr Urol. 2017 Feb;13(1):7-15. doi: 10.1016/j.jpurol.2016.09.003. Epub 2016 Oct 8.
Fetal megacystis is variably defined and understood. The literature on fetal megacystis was systematically reviewed, focusing on prenatal diagnosis, associations and outcomes. This yielded a total of 18 primary references and eight secondary references. Fetal megacystis has an estimated first-trimester prevalence of between 1:330 and 1:1670, with a male to female ratio of 8:1. In the first trimester, megacystis is most commonly defined as a longitudinal bladder dimension of ≥7 mm. Later in pregnancy, a sagittal dimension (in mm) greater than gestational age (in weeks) + 12 is often accepted. Megacystis can be associated with a thickened bladder wall, which has been objectively defined as >3 mm. Oligohydramnios is present in approximately half of all cases. The most common underlying diagnosis is posterior urethral valves (57%), followed by urethral atresia/stenosis (7%), prune belly syndrome (4%), megacystis-microcolon-intestinal-hypoperistalsis syndrome (MMIHS) (1%), and cloacal anomalies (0.7%). Karyotype anomalies are found in 15%, and include trisomy 18, trisomy 13 and trisomy 21. Ultrasound imaging alone is often insufficient to enable a definitive diagnosis, although it may indicate that a specific diagnosis is more likely. Overall, about 50% of reported fetuses with megacystis are terminated, but this proportion varies considerably between countries and over time. Prognostic stratification is evolving, with the most important factors being oligohydramnios, gestational age at diagnosis, degree of bladder enlargement, renal hyperechogenicity, karyotype, and sex.
This review demonstrated some consensus on the ultrasound criteria for defining fetal megacystis, and illustrated the spectrum of pathologies and their relative frequencies that can cause this condition. It also underlined important associated karyotype anomalies. To progress understanding of the natural history of enlarged fetal bladders, more accurate diagnostics are required, and risk stratification needs to be refined to facilitate prenatal counseling.
胎儿巨膀胱的定义和理解存在差异。对有关胎儿巨膀胱的文献进行了系统回顾,重点关注产前诊断、关联因素和结局。共获得18篇主要参考文献和8篇次要参考文献。胎儿巨膀胱在孕早期的估计患病率为1:330至1:1670,男女比例为8:1。在孕早期,巨膀胱最常被定义为膀胱纵径≥7毫米。在妊娠后期,矢状径(以毫米为单位)大于孕周(以周为单位)+12通常被认可。巨膀胱可能与膀胱壁增厚有关,膀胱壁增厚客观上被定义为>3毫米。约一半的病例存在羊水过少。最常见的潜在诊断是后尿道瓣膜(57%),其次是尿道闭锁/狭窄(7%)、Prune Belly综合征(4%)、巨膀胱-小结肠-肠蠕动不良综合征(MMIHS)(1%)和泄殖腔畸形(0.7%)。15%的病例存在核型异常,包括18三体、13三体和21三体。仅超声成像往往不足以做出明确诊断,尽管它可能提示某种特定诊断的可能性更大。总体而言,报告的患有巨膀胱的胎儿中约50%被终止妊娠,但这一比例在不同国家和不同时期差异很大。预后分层正在不断发展,最重要的因素是羊水过少、诊断时的孕周、膀胱增大程度、肾回声增强、核型和性别。
本综述展示了在定义胎儿巨膀胱的超声标准方面的一些共识,并阐明了可导致这种情况的一系列病理及其相对频率。它还强调了重要的相关核型异常。为了进一步了解胎儿膀胱增大的自然病史,需要更准确的诊断方法,并且需要完善风险分层以促进产前咨询。